Breast Cancer, Prostate Cancer
Conditions
Brief summary
The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic changes in the African Cancer genomes of the breast and prostate and identify the effects of social determinants of health and lifestyle factors on mutational landscape. Black individuals that have been diagnosed with pathologically confirmed prostate or breast cancer will be included. Detailed social determinants of health survey, blood and archived FFPE tissues will be collected. (Tier 1) All patient tissues will be subject to IHC for receptor status (ER, AR, PR Her2/neu). All patients with available germline DNA from blood will receive genetic screening using a Commercial gene panel testing. (Tier 2) Patient samples with a negative genetic screening will be subject to whole exome sequencing or banked for later RNA or methylation sequencing.
Interventions
OTHERStandard of Care
Drugs routinely administered for breast cancer per local standard.
Sponsors
Fox Chase Cancer Center
University of Miami Sylvester Comprehensive Cancer Center
Pfizer
The University of The West Indies
Kenya Medical Research Institute
University of Nairobi, Kenya
University of Abomey Calavi, Benin
Innovating Health International, Haiti
Institut de Recherche en Sciences de la Sante, Burkina Faso
Ministry of Health and Social Services, Namibia
Morgan State University
University of Alabama, Tuscaloosa
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients, 18-85 years of age, diagnosed with a pathologically confirmed cancer at any stage at diagnosis. Participant can have a history of a previous cancer we will control for previous history of cancer diagnosis in our analysis.
Exclusion criteria
* Patients age \<18 year, incarcerated patients, and patients whose medical decisions are made by proxy will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunohistochemistry | Year 1-2 | ER, PR, Her2 and AR status in breast and prostate tissues |
| Germline Mutations | Year 1-2 | Hereditary mutations in germline DND from breast and prostate |
| Mutational Landscape | Year 2 | tumor mutation burden in breast and prostate tissues |
Countries
United States
Outcome results
None listed